Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

NCT04879121 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions

DRUG: Larotrectinib Sulfate

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]